Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Poor outcomes in diabetic patients are observed across a range of human tumors, suggesting that cancer cells develop unique characteristics under diabetic conditions. Cancer cells exposed to hyperglycemic insults acquire permanent aggressive traits of tumor growth, even after a return to euglycemic conditions. Comparative genome-wide mapping of hyperglycemia-specific open chromatin regions and concomitant mRNA expression profiling revealed that the neuregulin-1 gene, encoding an established endogenous ligand for the HER3 receptor, is activated through a putative distal enhancer. Our findings highlight the targeted inhibition of NRG1-HER3 pathways as a potential target for the treatment breast cancer patients with associated diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is also evidence that changes in glucose and glucose metabolism can leave lasting epigenetic marks (Park et al., 2012; Pirola et al., 2010).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Park et al., 2012
Citations
Cites
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
MEME: discovering and analyzing DNA and protein sequence motifs
Bailey, T. L., Williams, N., Misleh, C., & Li, W. W. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl198 · Cited by 2,670
Olayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · cited 1×
“This reduced tumor growth is likely due to the lack of insulin, a factor with intrinsic mitogenic properties (9).”
BackgroundQuantifying similarity between motifs
Gupta, S., Stamatoyannopoulos, J. A., Bailey, T. L., & Noble, W. S. (2007) · Genome Biology · doi:10.1186/gb-2007-8-2-r24 · Cited by 2,058 · cited 1×
“High quality motifs were aligned against transcription factor motifs retrieved from JASPAR (30) and TRANSFAC (31) by using the TOMTOM software tool (32) to identify known transcription factor motifs that match the MEME predicted motifs.”
MethodJASPAR: an open-access database for eukaryotic transcription factor binding profiles
Sandelin, A. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh012 · Cited by 1,790
Guy, C. T., Cardiff, R. D., & Muller, W. J. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.3.954 · Cited by 1,631
CTCF: Master Weaver of the Genome
Phillips, J. E., & Corces, V. G. (2009) · Cell · doi:10.1016/j.cell.2009.06.001 · Cited by 1,552
Lin, E. Y., Jones, J. G., Li, P., Zhu, L., Whitney, K. D., Muller, W. J., & Pollard, J. W. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63568-7 · Cited by 1,107
Neuregulins: functions, forms, and signaling strategies
Falls, D. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00102-7 · Cited by 1,071
TRANSFAC: a database on transcription factors and their DNA binding sites
Wingender, E. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.1.238 · Cited by 1,054
Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., & Vigneri, R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0087 · Cited by 1,009
Fasting Serum Glucose Level and Cancer Risk in Korean Men and Women
Jee, S. H. (2005) · JAMA · doi:10.1001/jama.293.2.194 · Cited by 988
Identification of Heregulin, a Specific Activator of p185 erbB2
Holmes, W. E., Sliwkowski, M. X., Akita, R. W., Henzel, W. J., Lee, J., Park, J. W., Yansura, D., Abadi, N., Raab, H., Lewis, G. D., et al. (1992) · Science · doi:10.1126/science.256.5060.1205 · Cited by 962
Self-citationGiresi, P. G., Kim, J., McDaniell, R. M., Iyer, V. R., & Lieb, J. D. (2007) · Genome Research · doi:10.1101/gr.5533506 · Cited by 955
Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., & Hynes, N. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1537685100 · Cited by 950
Barone, B. B. (2008) · JAMA · doi:10.1001/jama.2008.824 · Cited by 881 · cited 1×
“D (DM) is a risk factor for enhanced cancer progression (1, 2).”
BackgroundA Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy
Lee-Hoeflich, S. T., Crocker, L., Yao, E., Pham, T., Munroe, X., Hoeflich, K. P., Sliwkowski, M. X., & Stern, H. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0380 · Cited by 629
A map of open chromatin in human pancreatic islets
Gaulton, K. J., Nammo, T., Pasquali, L., Simon, J. M., Giresi, P. G., Fogarty, M. P., Panhuis, T. M., Mieczkowski, P., Secchi, A., Bosco, D., et al. (2010) · Nature Genetics · doi:10.1038/ng.530 · Cited by 541
Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497
Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
MEDINA, P., & GOODIN, S. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.008 · Cited by 377
Prospective Study of Hyperglycemia and Cancer Risk
Stattin, P., Björ, O., Ferrari, P., Lukanova, A., Lenner, P., Lindahl, B., Hallmans, G., & Kaaks, R. (2007) · Diabetes Care · doi:10.2337/dc06-0922 · Cited by 352
Epigenetic phenomena linked to diabetic complications
Pirola, L., Balcerczyk, A., Okabe, J., & El-Osta, A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.188 · Cited by 239 · cited 1×
“” Notably, previous work established that hyperglycemia under different conditions can actively trigger epigenetic modifications resulting in long-lasting changes in gene expression (10).”
BackgroundAn Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells
Sheng, Q., Liu, X., Fleming, E., Yuan, K., Piao, H., Chen, J., Moustafa, Z., Thomas, R. K., Greulich, H., Schinzel, A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.047 · Cited by 234
Wilson, T. R., Lee, D. Y., Berry, L., Shames, D. S., & Settleman, J. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.07.011 · Cited by 161 · cited 4×
“In addition, the NRG1-HER3 loop in HER2-negative tumors contributes to drug sensitivity in the context of HER2-targeted therapies (14, 15, 23).”
BackgroundInfluentialHeuson, J.-C., & Legros, N. (1972) · PubMed · Cited by 151
Atlas, E., Cardillo, M., Mehmi, I., Zahedkargaran, H., Tang, C. K., & Lupu, R. (2003) · PubMed · Cited by 133
PANIC-ATTAC: A Mouse Model for Inducible and Reversible β-Cell Ablation
Wang, Z. V., Mu, J., Schraw, T. D., Gautron, L., Elmquist, J. K., Zhang, B. B., Brownlee, M., & Scherer, P. E. (2008) · Diabetes · doi:10.2337/db07-1631 · Cited by 66
Self-citationde Álava, E., Ocaña, A., Abad, M., Montero, J. C., Esparís-Ogando, A., Rodriguez, C. A., Otero, A. P., Hernández, T., Cruz, J. J., & Pandiella, A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.6850 · Cited by 66
Roles for neuregulins in human cancer
Stove, C. P., & Bracke, M. (2005) · Clinical & Experimental Metastasis · doi:10.1007/s10585-004-6917-6 · Cited by 54
Suppression of mammary gland tumorigenesis in diabetic rats
Cocca, C., Gutiérrez, A., Núñez, M., Croci, M., Martín, G., Cricco, G., Rivera, E., & BERGOC, R. M. (2003) · Cancer Detection and Prevention · doi:10.1016/s0361-090x(02)00130-7 · Cited by 11
Cited by
Influence of Metabolism on Epigenetics and Disease
Kaelin, W. G., & McKnight, S. L. (2013) · Cell · doi:10.1016/j.cell.2013.03.004 · Cited by 920
“There is also evidence that changes in glucose and glucose metabolism can leave lasting epigenetic marks (Park et al., 2012; Pirola et al., 2010).”
Obesity, Inflammation, and Cancer
Deng, T., Lyon, C. J., Bergin, S., Caligiuri, M. A., & Hsueh, W. A. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044359 · Cited by 794
Obesity and cancer—mechanisms underlying tumour progression and recurrence
Park, J., Morley, T. S., Kim, M., Clegg, D. J., & Scherer, P. E. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.94 · Cited by 790
Self-citationHyperglycemia as a Risk Factor for Cancer Progression
Ryu, T. Y., Park, J., & Scherer, P. E. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.5.330 · Cited by 331
Self-citationMetabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer
Liu, S., Zhang, X., Wang, W., Li, X., Sun, X., Zhao, Y., Wang, Q., Li, Y., Hu, F., & Ren, H. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02165-x · Cited by 246
Metadata
- Authors
- Park, J., Sarode, V. R., Euhus, D., Kittler, R., & Scherer, P. E.
- Affiliations
- Touchstone Diabetes Center and Departments of
- Harold C. Simmons Comprehensive Cancer Center (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2012-12-03
- Volume
- 109
- Issue
- 51
- Pages
- 21058-21063
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3529089
- OpenAlex
- W2030494575
- Cited by
- 44
- References
- 32
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 2 · 2016: 4 · 2015: 2 · 2014: 3 · 2013: 2
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- U.S. Department of Defense
- Cancer Prevention and Research Institute of Texas
- National Institutes of Health
- National Cancer Institute (R01CA112023, BC085909, P30CA142543)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK081182, PL1DK081182, 01-DK55758, R01DK055758, P01DK088761)
- Medical Research and Materiel Command
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- neuregulin-1, hyperglycemia, diabetes mellitus, breast cancer, tumor aggressiveness, distal enhancers, open chromatin, gene expression profiling, therapeutic target
- MeSH terms
- Animals, Breast Neoplasms, Diabetes Mellitus, Gene Expression Regulation, Cricetinae, Humans, Hyperglycemia, RNA, Messenger, Tumor Cells, Cultured, Signal Transduction, CHO Cells, Genomic Imprinting, Oligonucleotide Array Sequence Analysis, Neuregulin-1, Receptor, ErbB-3, Epigenesis, Genetic, Cell Line, Tumor, Cell Proliferation, Mice, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.